×

Sign In

Search
Home

Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4

By Thomson Reuters Nov 7, 2024 | 12:20 AM

COPENHAGEN (Reuters) – Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.

(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)

Trump win casts fresh doubts over Wall Street's China strategy

UBS pilots blockchain-based payment system

French minister slams PSG's 'Free Palestine' banner at soccer match

Italy's Banco BPM launches $1.7 billion bid for asset manager Anima

Asia ex-China equities have biggest monthly foreign outflow in nearly 2-1/2 years

Joerg Kukies to become new German finance minister, reports broadcaster

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2024. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.